These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34031004)

  • 1. Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone.
    Singh A; Thota S; Bradley T; Griffiths EA; Faber MG; Sadek S; Przespolewski A; Thompson JE; Baron J; Cronin T; Attwood K; Madarang EC; Watts J; Wang ES
    Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):613-620. PubMed ID: 34031004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
    Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
    Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Immunol; 2021; 12():683595. PubMed ID: 34484181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
    Muresan B; Mamolo C; Cappelleri JC; Mokgokong R; Palaka A; Soikkeli F; Heeg B
    Future Oncol; 2021 Aug; 17(22):2883-2892. PubMed ID: 33858190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML).
    Vegunta R; Harel R; Steinberg A
    Cureus; 2022 Jun; 14(6):e26240. PubMed ID: 35898381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
    Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
    Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
    Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
    J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
    Ito Y; Wakita A; Takada S; Mihara M; Gotoh M; Ohyashiki K; Ohtake S; Miyawaki S; Ohnishi K; Naoe T
    Int J Hematol; 2012 Oct; 96(4):485-91. PubMed ID: 22956429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemtuzumab ozogamicin for
    Lambert J; Pautas C; Terré C; Raffoux E; Turlure P; Caillot D; Legrand O; Thomas X; Gardin C; Gogat-Marchant K; Rubin SD; Benner RJ; Bousset P; Preudhomme C; Chevret S; Dombret H; Castaigne S
    Haematologica; 2019 Jan; 104(1):113-119. PubMed ID: 30076173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.
    Cairoli R; Furneri G; Di Virgilio R; Veggia B; Ferrara F
    BMC Health Serv Res; 2023 Jan; 23(1):36. PubMed ID: 36642712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
    Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Sauer T; Crysandt M; Rank A; Behringer D; Teichmann L; Görner M; Trappe RU; Röllig C; Krause S; Hanoun M; Hopfer O; Held G; Buske S; Fransecky L; Kayser S; Schliemann C; Schaefer-Eckart K; Al-Fareh Y; Schubert J; Geer T; Kaufmann M; Brecht A; Niemann D; Kieser M; Bornhäuser M; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Schlenk RF
    Trials; 2021 Nov; 22(1):765. PubMed ID: 34732236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
    Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P;
    Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.
    Pawinska-Wasikowska K; Czogala M; Skoczen S; Surman M; Rygielska M; Ksiazek T; Pac A; Wieczorek A; Skalska-Sadowska J; Samborska M; Wachowiak J; Chaber R; Tomaszewska R; Szczepanski T; Zielezinska K; Urasinski T; Moj-Hackemer M; Kalwak K; Kozlowska M; Irga-Jaworska N; Balwierz W; Bukowska-Strakova K
    Front Immunol; 2023; 14():1268993. PubMed ID: 38187390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience.
    Açar İH; Guvenc B
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984499
    [No Abstract]   [Full Text] [Related]  

  • 17. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Bourne G; Diebold K; Espinoza-Gutarra M; Al-Kadhimi Z; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R; Jamy O
    Leuk Res; 2024 Apr; 139():107467. PubMed ID: 38460432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.
    Genthon A; Brissot E; Malard F; van de Wyngaert Z; Bonnin A; Banet A; Marjanovic Z; Ikhlef S; Lapusan S; Sestili S; Corre E; Paviglianiti A; Adaeva R; 'Hammedi-Bouzina FM; Labopin M; Dulery R; Mohty M; Legrand O
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):791-796. PubMed ID: 32741743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
    Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
    Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemtuzumab Ozogamicin in
    Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
    J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.